Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawed

BMJ. 1998 Apr 18;316(7139):1241-2.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anticholesteremic Agents / therapeutic use*
  • Clinical Trials as Topic / methods
  • Coronary Disease / prevention & control*
  • Data Collection / standards
  • Humans
  • Pravastatin / therapeutic use*

Substances

  • Anticholesteremic Agents
  • Pravastatin